Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201312-15 Generation of lead compound of transcutaneous delivery peptide (TDP) for atopic dermatitis(Immunology, Protein) [03.31.2014]

PRINT

Development and Market Objectives

Our primary objective is to develop a safe and unique biomaterial for the treatment of intractable allergic disease (atopic dermatitis). A cell-penetrating peptide has been investigated with extensive research and developed into a transcutaneous delivery peptide, a drug delivery system that can penetrate the skin barrier.

Unmet Medical Need & Target Patients

(1) Target Patients
Atopic dermatitis is a chronically recurring typical allergy-type skin disease frequently accompanied by severe itchiness. The condition is widespread from toddlers to adults and the number of reported cases continues to rise. The primary target patients for our therapeutic are those with evident dermatitis symptoms including itching, dryness and eczema.

(2) Unmet Medical Needs
Common treatment modalities are prescribed according to treatment stage.
 

Degree Treatment Stage Treatment Method
Dry skin 1 Basic Treatment: Moisturization, inflammatory suppression, identification of allergen
Slight ~ Moderately Serious 2 Prescription of mild local steroid agents and a local calcineurin inhibitor
Moderately Serious ~ Serious 3 Prescription of a high potency local calcineurin inhibitor
Serious (incurable) 4 Systemic Treatment: systemic steroid prescription with cyclosporine A, UV treatment
Table 1. Common treatments for atopic dermatitis

Progress in the development of safe and effective medicines for the treatment of atopic dermatitis has been limited (Datamonitor). This has been largely due to the fact that the modes of onset and pathological mechanisms have only been recently elucidated.
Local steroid application is the most common treatment, but is only suitable for providing temporary relief due to side effects including skin shrinkage, blood vessel extension, bleaching, the appearance of purple spots and issues with the development of tolerance. Oral and intravenous steroid treatment is used for moderately serious atopic dermatitis. However, despite high efficacy, the steroid rebound effect is considered as a risk when prescribing this treatment. The side effect can manifest as growth impairment, obesity and other complications caused by an increased appetite. Similarly, high risks are associated with CyA and calcineurin inhibitors including red spots, flu symptoms and headaches when used continuously. As such, widespread dissatisfaction and considerable unmet medical needs exist for the treatment of atopic dermatitis.
New treatments that are safer and address the underlying pathophysiology of atopic dermatitis are urgently needed. 

 

Status

(1) We have confirmed a highly effective human cell-penetrating peptide sequence that can deliver functional biomaterial (both protein and peptide) into cells.

(2) Optimization of the cell-penetrating peptide is ongoing, to improve the delivery of functional biological payloads into cells through the epidermis and dermis with high efficiency.

(3) Two types of candidate protein have been selected, based on the mode of action characterized for atopic dermatitis.

Intellectual Property

Patents have been filed covering 6 types of cell-penetrating peptide, including sequence and domain information, as well as the cargo delivery functionality.
(Application Numbers: 2012-0152966 / 10-2013-0120096 / 10-2013-0120095 / 10-2013-0120094). 

Competitive Advantages

12

This treatment is projected to deliver therapeutic proteins directly into cells safely and effectively using a cell-penetrating peptide based on a human protein sequence that is distinct from existing cell penetrating peptide methods (TAT, VP22: viral origin).
Using proteins and peptides of human origin for skin treatment confers additional advantages in terms of safety and efficiency.
The method for intracellular delivery of proteins and peptides for the inhibition of atopic dermatitis signalling is in an excellent competitive position because the market for atopic dermatitis treatment is still largely dependent on steroid agents, while the effect of newly-developed monoclonal antibodies have not been verified.  
In addition, the skin penetrating peptide currently under development has potential applications in diverse fields including not only atopic dermatitis, but also for other skin diseases and skin care needs.
 

Indication

atopic dermatitis

Research Period

Feb, 2013 ~Jun, 2014

Company

Hanyang University

Developmental Stage

Lead Generation

Additional Information

Contact Information

Contact
Address Company Name: Hanyang University (Hanyang University Department of Biology)
WebSite Homepage: http://www.hanyang.ac.kr (Department of Life Science: bio.hanyang.ac.kr) Contact Person: Professor Choi, Je-Min
E-mail: jeminchoi@hanyang.ac.kr Contact: 82-2-2220-4765

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code